Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs.
Endogena has raised $21.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Endogena's investors include DEFTA Partners, Centenara Labs.
Endogena is headquartered in San Francisco, United States.
Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs.
Endogena is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endogena — Funding & Investors." VCBacked, December 13, 2021, https://www.vcbacked.co/company/endogena. Accessed September 30, 2026.
VCBacked. (2021). Endogena — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/endogena
{{cite web |title=Endogena — Funding & Investors |url=https://www.vcbacked.co/company/endogena |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated